The Trip Report

Special Dispatch: FDA Rejects Lykos’ MDMA Assisted Therapy Application

31 snips
Aug 13, 2024
Dr. Carlene MacMillan, a Harvard-trained psychiatrist and Chief Medical Officer at Osmind, shares her insights on the recent FDA rejection of Lykos Therapeutics' MDMA-assisted therapy. She discusses the complexities of psychiatric trials, research misconduct allegations, and the role of reliable data in therapy approval. The conversation also highlights challenges in integrating innovative treatments into the healthcare system and the push for value-based care. Dr. MacMillan emphasizes the importance of collaboration and the future of psychedelic therapies in mental health.
Ask episode
Chapters
Transcript
Episode notes